Octapharma Group publishes 2017 annual results reporting revenue of €1.72 billion and operating income of €349 million

Lachen, Switzerland, March 1st, 2018: Over the last six years, the Octapharma Group has accomplished...

Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia A

Lachen, Switzerland, January 22nd, 2018: Octapharma is delighted to announce the publication of fina...


Octapharma’s success is the result of the combined contribution of all employees, what we call “the human factor”. To embark on a challenging and rewarding career in an innovative biopharmaceutical organization, explore our global opportunities